Related Experiment Videos
Techniques: Recent developments in computer-aided engineering of GPCR ligands using the human adenosine A3 receptor
Stefano Moro1, Giampiero Spalluto, Kenneth A Jacobson
1Molecular Modeling Section, Dipartimento di Scienze Farmaceutiche, Università di Padova, Via Marzolo 5, I-35131 Padova, Italy. stefano.moro@unipd.it
Trends in Pharmacological Sciences
|January 5, 2005
Summary
G-protein-coupled receptors (GPCRs) are key drug targets. This review highlights adenosine A3 receptor antagonists and a synergistic approach combining computational modeling and experiments for drug discovery.
Area of Science:
- Biochemistry
- Pharmacology
- Structural Biology
Background:
- G-protein-coupled receptors (GPCRs) are a vast family of signal-transducing proteins involved in numerous physiological processes.
- GPCRs are implicated in various human diseases and represent a significant class of drug targets.
- The rhodopsin crystal structure has enabled advancements in GPCR modeling and structure-based drug design.
Purpose of the Study:
- To review recent developments concerning adenosine receptors, a specific class of GPCRs.
- To focus on adenosine A3 receptor antagonists.
- To discuss an iterative, bi-directional approach integrating computational modeling and experimental validation.
Main Methods:
- Review of existing literature on adenosine receptors and antagonists.
- Application of homology modeling based on GPCR structures.
- Iterative hypothesis generation through modeling and experimental testing.
Main Results:
- The review covers recent progress in understanding adenosine A3 receptor antagonists.
- The bi-directional approach demonstrates successful synergy between theoretical modeling and experimental data.
- Refinement of models based on experimental findings enhances drug design strategies.
Conclusions:
- The integrated approach of modeling and experimentation is highly effective for GPCR research.
- Adenosine A3 receptor antagonists are a promising area for therapeutic development.
- Advancements in GPCR structural biology continue to drive drug discovery efforts.